Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009

Evidence-based Series #8-1 Version 3.2009: Section 1
Systemic Adjuvant Therapy for Patients at High Risk for
Recurrent Melanoma: Updated Guideline Recommendations 2009
T. Petrella, S. Verma, K. Spithoff, I. Quirt, D. McCready,
and the Melanoma Disease Site Group
A Quality Initiative of the
Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)
Developed by the Melanoma Disease Site Group
Current Report Date: June 22, 2009
Original Report Date: June 30, 2004
INTENDED USERS
These guidelines are intended for use by clinicians and health care providers involved in the management and referral of patients with resected melanoma at high risk for recurrence.
QUESTION
What systemic therapy should clinicians recommend to patients who have been rendered disease free following the resection of cutaneous melanomas and who are at high risk for subsequent recurrence?
Outcomes of interest include overall survival (OS), disease-free survival (DFS), adverse effects, and quality of life.
TARGET POPULATION
These recommendations apply to adult patients with high-risk malignant melanoma who are rendered disease free following resection. For this practice guideline, high risk is defined as patients in the following clinical states:
- primary melanoma with tumour thickness ≥4.0 mm,
- primary melanoma with in-transit metastases,

abrir aquí para acceder al documento AHRQ NGC [Cancer Care Ontario]en archivo PDF completo (43 páginas):
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34373